Allarity Therapeutics, Inc. (ALLR) Dividend History

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment. The company specializes in identifying targeted therapies based on tumor biology and genetic profiles to improve patient outcomes. Previously known as Oncothyreon Inc., Allarity aims to advance its pipeline through research and partnerships in oncology.

24 School St., 2nd Floor, Boston, MA, 02108
Phone: 401-426-4664
Website: https://www.allarity.com

Dividend History

Allarity Therapeutics, Inc. currently does not pay dividends

Company News

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

Allarity Therapeutics announced a research collaboration with the Indiana Biosciences Research Institute to further study the dual mechanism of action of their drug candidate, stenoparib, which inhibits both PARP and the WNT signaling pathway.

GlobeNewswire Inc.
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics announced the enrollment of the first patient in a new Phase 2 clinical trial of its drug stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The trial aims to accelerate the development of stenoparib and its companion diagnostic.

GlobeNewswire Inc.
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics announces a Phase 2 trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer, which is fully funded by the U.S. Veterans Administration.

GlobeNewswire Inc.
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics announced the start of a new Phase 2 clinical trial for its drug stenoparib in advanced ovarian cancer patients. The trial aims to generate data for a pivotal registration trial and advance the stenoparib-DRP companion diagnostic toward FDA approval.

GlobeNewswire Inc.
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics is expanding its Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, to accelerate its development for advanced ovarian cancer. The trial aims to optimize the dose, refine patient selection criteria, and enhance understanding of stenoparib's mechanism of action.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 14:49:30 UTC